Last reviewed · How we verify
Oxybutynin Transdermal Patch
Oxybutynin is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.
Oxybutynin is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency, Neurogenic detrusor overactivity in spinal cord injury patients.
At a glance
| Generic name | Oxybutynin Transdermal Patch |
|---|---|
| Also known as | Ditropan XL |
| Sponsor | University of California, Davis |
| Drug class | Anticholinergic agent |
| Target | M3 muscarinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Urology / Neurology |
| Phase | Phase 3 |
Mechanism of action
Oxybutynin antagonizes M3 muscarinic receptors on detrusor muscle, which suppresses the parasympathetic-mediated contractions responsible for urinary urgency and incontinence. The transdermal patch formulation provides sustained drug delivery over several days, improving tolerability compared to oral administration by reducing peak plasma concentrations and associated anticholinergic side effects.
Approved indications
- Overactive bladder with symptoms of urge incontinence, urgency, and frequency
- Neurogenic detrusor overactivity in spinal cord injury patients
Common side effects
- Dry mouth
- Application site erythema or pruritus
- Constipation
- Blurred vision
- Dizziness
Key clinical trials
- Oxybutynin for Post-surgical Bladder Pain and Urgency (PHASE3)
- Transdermal Versus Oral Oxybutynin in Pediatric OAB (NA)
- Effect of Heat on Oxybutynin Release and Absorption From Oxybutynin Products (EARLY_PHASE1)
- Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream. (PHASE3)
- Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition (PHASE4)
- A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxybutynin Transdermal Patch CI brief — competitive landscape report
- Oxybutynin Transdermal Patch updates RSS · CI watch RSS
- University of California, Davis portfolio CI